pharma · Psoriasis Vulgaris · Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
LEO Pharma US
LEO Pharma A/S
LEO Pharma A/S is a pharma organization headquartered in Ballerup, DK. Primary therapeutic focus areas include Psoriasis Vulgaris, Moderate-to-severe plaque psoriasis and a body weight ≥120 kg., Mild to severe palmoplant
Madison, USA HQ
1908 Founded
75 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Madison, USA
- Founded
- 1908
- Employees
- 75
- Programs
- 7
- Drugs
- 11
- Patents
- 0
Adtralza 150 mg solution for injection in pre-filled syringe
Phase 2 · small molecule · Treatment of moderate-to-severe Atopic dermatitis
Adtralza 150 mg solution for injection in pre-filled syringe for Treatment of moderate-to-severe Atopic dermatitis is a Phase 2 program (small_molecule) at LEO Pharma A/S with 1 ClinicalTrials.gov record(s).
Internal code LP0162-1335
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- LEO Pharma A/S
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Treatment of moderate-to-severe Atopic dermatitis
- Status
- active
- Trials
- 1